Avidicure
Develops AVC-Boosters to enhance NK cells, activate the immune system, and provide broad anti-tumor responses for cancer immunotherapy.
Employees
Enterprise value
$193—290m
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor investor | €0.0 | round | |
* | €44.0m | Seed | |
| Total Funding | 000k | ||
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads